IP Library Granted Patent US 8,496,951
Granted Patent B2
US 8,496,951 · App. 13/370,202 · Granted Jul 30, 2013

Compositions containing aromatic aldehydes and their use in treatments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,496,951
App. No.
13/370,202
Granted
Jul 30, 2013
Kind
B2
Abstract

Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.

Claims (16)

1. A composition comprising (1) an effective skin-condition alleviating amount of a first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde; (2) niacinamide; and (3) a pharmaceutically or cosmetically acceptable topical carrier, wherein the skin-condition is selected from the group consisting of skin inflammation, aging, sunburn, microbial infection, psoriasis, acne, rosacea, and eczema.

2. The composition of claim 1 in a sustained release dosage form.

3. The composition of claim 1 , wherein the first active ingredient is 4-ethoxybenzaldehyde.

4. The composition of claim 1 , wherein the pharmaceutically or cosmetically acceptable topical carrier is a lotion.

5. The composition of claim 1 , wherein the pharmaceutically or cosmetically acceptable topical carrier is a cream.

6. The composition of claim 1 , wherein the effective skin-condition alleviating amount of the first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde is between 0.001% to 20% by weight.

7. The composition of claim 3 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is between 1.0% and 10% by weight.

8. The composition of claim 7 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is 1.0% by weight.

9. A transdermal composition, comprising a transdermal preparation of (1) an effective skin-condition alleviating amount of a first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde; (2) niacinamide; and (3) a pharmaceutically or cosmetically acceptable carrier, wherein the skin-condition is selected from the group consisting of skin inflammation, aging, sunburn, microbial infection, psoriasis, acne, rosacea, and eczema.

10. The transdermal composition of claim 9 in a sustained release dosage form.

11. The transdermal composition of claim 9 , wherein the first active ingredient is 4-ethoxybenzaldehyde.

12. The transdermal composition of claim 9 , wherein the pharmaceutically or cosmetically acceptable carrier is a lotion.

13. The transdermal composition of claim 9 , wherein the pharmaceutically or cosmetically acceptable carrier is a cream.

14. The transdermal composition of claim 9 , wherein the effective skin-condition alleviating amount of the first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde is between 0.001% to 20% by weight.

15. The transdermal composition of claim 11 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is between 1.0% and 10% by weight.

16. The transdermal composition of claim 15 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is 1.0% by weight.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2013
From: SKINMEDICA, INC.
To: ALLERGAN, INC.
Reel/Frame 029752/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2012
From: MERZ AESTHETICS, INC.
To: SKINMEDICA, INC.
Reel/Frame 028255/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: MERZ AESTHETICS, INC.
To: SKINMEDICA, INC.
Reel/Frame 028243/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2012
From: FULLER, BRYAN; ENGLES, CHARLES R.; PILCHER, BRIAN KEITH
To: CUTANIX CORPORATION
Reel/Frame 028145/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2012
From: CUTANIX CORPORATION
To: BIOFORM MEDICAL, INC.
Reel/Frame 028145/0383 →
CHANGE OF NAME Recorded May 2, 2012
From: BIOFORM MEDICAL, INC.
To: MERZ AESTHETICS, INC.
Reel/Frame 028146/0545 →